Trial Profile
A Study to Evaluate the Prognostic Value of Natalizumab Saturation on T Cells for the Recurrence of Clinical and Radiological Disease Activity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- 02 Dec 2015 New trial record